发布求助
文献互助 智能选刊 最新文献

Drug news & perspectives最新文献

筛选
英文 中文
The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors? 抗环瓜氨酸肽抗体在类风湿关节炎中的价值:是否意味着新的危险因素?
Drug news & perspectives Pub Date : 2009-11-01 DOI: 10.1358/dnp.2009.22.9.1416992
Francisco Javier López-Longo, Silvia Sánchez-Ramón, Luis Carreño
{"title":"The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?","authors":"Francisco Javier López-Longo,&nbsp;Silvia Sánchez-Ramón,&nbsp;Luis Carreño","doi":"10.1358/dnp.2009.22.9.1416992","DOIUrl":"https://doi.org/10.1358/dnp.2009.22.9.1416992","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes chronic inflammation of the joints and several extra-articular manifestations that account for increased morbimortality of these patients. The involvement of B cells in RA pathophysiology was recognized early, with the discovery of rheumatoid factor antibody. Recently, a number of autoantibodies against citrullinated proteins have been described, of which anti-cyclic citrullinated peptide (anti-CCP) is the most specific for RA. A cohort of 937 patients with RA was studied to determine the clinical correlates of anti-CCP antibodies. The presence of anti-CCP antibodies correlated with worse joint involvement and several extra-articular manifestations, i.e., higher incidence of ischemic heart disease independent of classic cardiovascular factors and higher mortality rate. A multivariate logistic regression model showed that only anti-CCP antibodies were independently associated with the development of ischemic heart disease in patients with RA. The clinical value of anti-citrullinated protein antibodies and the relevance of anti-CCP antibodies in daily clinical practice are reviewed.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"543-8"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28646251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Blocking conversion of GABAergic inhibition as a potential mechanism of propofol-mediated brain protection following resuscitation. 阻断 GABA 能抑制的转换，作为异丙酚介导的复苏后大脑保护的潜在机制。
Drug news & perspectives Pub Date : 2009-11-01 DOI: 10.1358/dnp.2009.22.9.14228870
Hui Zhang, Xiaopeng Mei, Wei Wang, Xude Sun
{"title":"Blocking conversion of GABAergic inhibition as a potential mechanism of propofol-mediated brain protection following resuscitation.","authors":"Hui Zhang, Xiaopeng Mei, Wei Wang, Xude Sun","doi":"10.1358/dnp.2009.22.9.14228870","DOIUrl":"10.1358/dnp.2009.22.9.14228870","url":null,"abstract":"<p><p>Animal experiments and clinical studies have indicated that propofol pretreatment significantly improves post-resuscitation recovery of neuronal functions. However, current theories on how propofol enhances the inhibitory effects of gamma-aminobutyric acid (GABA) cannot fully explain its protective action on the brain. Recent studies have suggested that during the process of resuscitation, the effect of GABA is converted from inhibitory to excitatory, via a mechanism that is closely associated with activation of microglia and downregulation of the K(+)-Cl(-) cotransporter 2 (KCC2). We propose a hypothesis that propofol protects the brain through inhibiting the conversion of GABAergic inhibition into excitation during resuscitation. Activation of microglia, downregulation of KCC2, and correlations between these effects and the protective actions of propofol, may reveal the molecular mechanisms of propofol-mediated brain protection. Further investigations into the protective mechanisms of general anesthetics on the brain represented by propofol will help to guide rational clinical drug use, and will contribute to the discovery and development of novel brain-protective drugs to prevent perioperative cardiopulmonary resuscitation-associated brain injury.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"525-9"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28646248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Molecule of the month. Vadimezan. 本月分子。Vadimezan。
Drug news & perspectives Pub Date : 2009-11-01
{"title":"Molecule of the month. Vadimezan.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"555"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28646252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of incretin-based therapies in the management of type 2 diabetes. 以肠促胰岛素为基础的治疗在2型糖尿病治疗中的作用。
Drug news & perspectives Pub Date : 2009-11-01 DOI: 10.1358/dnp.2009.22.9.1434633
Prabirkumar Bandyopadhyay
{"title":"The role of incretin-based therapies in the management of type 2 diabetes.","authors":"Prabirkumar Bandyopadhyay","doi":"10.1358/dnp.2009.22.9.1434633","DOIUrl":"https://doi.org/10.1358/dnp.2009.22.9.1434633","url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"559-67"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28646253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Histone deacetylases as targets for the treatment of human neurodegenerative diseases. 组蛋白去乙酰化酶作为治疗人类神经退行性疾病的靶点。
Drug news & perspectives Pub Date : 2009-11-01 DOI: 10.1358/dnp.2009.9.1428871
Santosh R D'Mello
{"title":"Histone deacetylases as targets for the treatment of human neurodegenerative diseases.","authors":"Santosh R D'Mello","doi":"10.1358/dnp.2009.9.1428871","DOIUrl":"https://doi.org/10.1358/dnp.2009.9.1428871","url":null,"abstract":"<p><p>Histone deacetylases (HDACs) are a family of proteins that play an important role in regulating transcription as well as the function of a variety of cellular proteins. While these proteins are expressed abundantly in the brain, little is known about their roles in brain function. A growing body of evidence suggests that HDACs regulate neuronal survival. Results from studies conducted in vertebrate and mammalian experimental systems indicate that while some of these proteins are involved in promoting neuronal death, a majority of the HDACs studied thus far protect against neurodegeneration. Here we review the research performed on the role played by individual members of the HDAC family in the regulation of neuronal death. Chemical inhibitors of HDACs have been used in a variety of models of neurodegenerative disorders. We summarize the results from these studies, which indicate that HDAC inhibitors show great promise as therapeutic agents for human neurodegenerative disorders.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"513-24"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934413/pdf/nihms555774.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28646250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 47
From molecules to medicine: a future cure for preeclampsia? 从分子到药物:子痫前期的未来治疗方法?
Drug news & perspectives Pub Date : 2009-11-01 DOI: 10.1358/dnp.2009.22.9.1435464
Mark K Santillan, Donna A Santillan, Curt D Sigmund, Stephen K Hunter
{"title":"From molecules to medicine: a future cure for preeclampsia?","authors":"Mark K Santillan,&nbsp;Donna A Santillan,&nbsp;Curt D Sigmund,&nbsp;Stephen K Hunter","doi":"10.1358/dnp.2009.22.9.1435464","DOIUrl":"https://doi.org/10.1358/dnp.2009.22.9.1435464","url":null,"abstract":"<p><p>In the United States, preeclampsia (PreE) affects 5-7% of all pregnancies, yet represents 15% of all maternal-fetal morbidity and mortality. PreE causes fetal growth restriction, oligohydramnios, fetal death, and maternal seizures, stroke, cerebrovascular hemorrhage and death. It has immediate and potentially long-term effects on both the fetus and mother. To date, the molecular pathogenesis of PreE is largely unknown. Multiple pathways, including dysfunctional angiogenesis, inappropriate placentation, oxidative stress and an altered immunological milieu have been proposed as key players in the development of PreE. In addition, genetic factors in all of these pathways are essential components in the etiology of this disease. This review introduces the clinical presentation of PreE and its particular disease phenotype that has prompted some of the molecular investigations of its etiology. Evidence of the many molecular pathways involved in the pathogenesis of PreE, as well as the therapeutic investigations targeting these pathways, is presented.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 9","pages":"531-41"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28646249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Chronicles in drug discovery. 药物发现编年史。
Drug news & perspectives Pub Date : 2009-10-01
Patrick Cole, Sylvia Vasiliou
{"title":"Chronicles in drug discovery.","authors":"Patrick Cole,&nbsp;Sylvia Vasiliou","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 8","pages":"500-3"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28599601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dendritic cell modulation as a new interventional approach for the treatment of asthma. 树突状细胞调节作为治疗哮喘的一种新的介入方法。
Drug news & perspectives Pub Date : 2009-10-01
Vincent Lombardi, Omid Akbari
{"title":"Dendritic cell modulation as a new interventional approach for the treatment of asthma.","authors":"Vincent Lombardi,&nbsp;Omid Akbari","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Dendritic cells (DCs) have a central role in the immune system, as they control the adaptive immune response and mediate both protective immunity and the maintenance of immune tolerance to self antigens. In this review, we will summarize the recent advances regarding the subsets of DCs and how they regulate the differentiation of naive CD4(+) T cells towards different populations of T helper cells. We will particularly describe the role of DCs in the development and regulation of allergic diseases and asthma, and discuss the capacity of DCs to induce proallergenic Th2 cells versus regulatory T cells. Undoubtedly, tolerogenic DCs play a crucial role in the induction of regulatory cells. Understanding the biology of these cells will help us design novel strategies to cure or prevent allergic diseases and asthma.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 8","pages":"445-51"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845716/pdf/nihms181846.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28599649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabodies: molecular engineering and therapeutic applications. 糖尿病:分子工程和治疗应用。
Drug news & perspectives Pub Date : 2009-10-01
Chengbin Wu
{"title":"Diabodies: molecular engineering and therapeutic applications.","authors":"Chengbin Wu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Bispecific antibodies are capable of interacting with two different antigens and when selected properly, can redirect cytotoxic effector cells to tumor cells for effective killing. These antibodies are therefore of great interest in the research and development of cancer treatment. Over the last two decades, many different bispecific antibody-derived molecular formats have been described, among which diabodies represent an important class of engineered molecules that possess tumor-targeting function. Since diabodies were first introduced in the early 1990s, extensive efforts have been made to optimize their physicochemical and key functional properties, as well as to provide in vivo proof of concept of their antitumor efficacy in animal models. With the clinical validation of the T-cell-retargeting mechanism for cancer therapy currently in place, there is renewed interest in this bispecific class of biologic molecules, with additional novel formats being described in recent years. Even with the remaining challenges of the manufacturing yields and drug-like properties, diabodies and their derivatives remain viable therapeutic modalities that warrant further consideration and development.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 8","pages":"453-8"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28599650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecule of the month. XOMA-052. 本月分子。xoma - 052。
Drug news & perspectives Pub Date : 2009-10-01
{"title":"Molecule of the month. XOMA-052.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"22 8","pages":"497"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28599654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信